АЛДАРА

Quick links to important sections

АЛДАРА

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of АЛДАРА

Quick Facts

Property Description
Active ingredient Imiquimod (INN)
Form Topical Cream (single-use sachet)
Pharmacological class Immune Response Modifier (IRM)
Common purpose To activate the body's local immune system
Origin Synthetic compound

АЛДАРА: Defining the Active Ingredient and Pharmacological Class

АЛДАРА is a prescription-only medicine containing the single active ingredient Imiquimod (INN), which is a synthetic compound belonging to the imidazoquinolone amine family. It is formally classified within the pharmacological group of Immune Response Modifiers (IRMs). This classification reflects that the drug's fundamental purpose is to modulate the body's local immune activity rather than directly destroying tissue or pathogens. Imiquimod is recognized for its ability to induce this specific type of targeted immune response in the skin.

What is the Composition and Form of АЛДАРА?

The pharmaceutical form of АЛДАРА is a topical cream intended exclusively for cutaneous application to the skin surface. Imiquimod is formulated as a single-ingredient product within an oil-in-water vanishing cream base, a design intended for local delivery. The medication is typically provided in single-use sachets, a specific characteristic of this preparation designed to ensure hygienic and accurate application. This cream form minimizes systemic absorption, focusing the drug's immune-modulating activity on the area of the skin where it is applied.

General Purpose of the Immune Response Modifier

The general purpose of Imiquimod is to help the body mount a localized immune defense against abnormal skin cells. By activating local immune cells, Imiquimod helps trigger a cascade that enables the immune system to recognize and eliminate cells affected by viruses or exhibiting harmful cellular changes. This principle serves the purpose of achieving gradual, immune-mediated clearance of the targeted abnormality.

Regulatory References

  1. NIH StatPearls - Imiquimod (DB00724)

What side effects are possible with АЛДАРА?

Possible side effects and safety information

The official safety documentation for АЛДАРА (Imiquimod Topical Cream) outlines possible adverse effects primarily focused on the application site and systemic, flu-like symptoms. These reactions are categorized according to regulatory frequency classifications.


Frequency-Classified Adverse Reactions

Classification Examples of Reactions
Very Common (≥ 1/10) Application site pain, pruritus (itching), and erythema (redness).
Common (≥ 1/100 to < 1/10) Headache, fatigue, fever, nausea, myalgia (muscle pain), arthralgia (joint pain), and local irritation or burning.
Uncommon (≥ 1/1,000 to < 1/100) Influenza-like illness, rigors, depression, insomnia, and gastrointestinal effects like vomiting or diarrhea.

Documented Safety Constraints and Serious Reactions

The product's safety profile includes specific constraints documented in regulatory labeling. The cream is not recommended for use on broken skin, as this may increase the risk of systemic absorption. A mandatory constraint exists regarding avoidance of sunlight and sunlamps due to the potential for severe photosensitivity reactions.

Serious Adverse Reactions officially noted include the development of severe local inflammatory reactions, such as pronounced skin weeping or erosion, which may necessitate temporary cessation of the product. Rare cases of localized complete and persistent depigmentation (hypopigmentation) have also been reported. Furthermore, severe vulvar swelling leading to urinary retention is specifically documented as a serious reaction in female patients treating external genital warts.

Safety is not established for specific populations, including immunosuppressed individuals and certain pediatric age groups. Local skin reactions are generally anticipated to be most intense at the beginning of treatment and are expected to resolve or decrease in intensity after therapy is concluded.

Overdose and Emergency Response

The official documentation for Imiquimod cream addresses two primary types of overdose exposure: accidental ingestion and the application of excessive cream.

Documented Overdose Manifestations

Category Official Regulatory Statement
Systemic Overdose (Ingestion) Associated with central nervous system and cardiovascular symptoms, including confusion, blurred vision, nausea, and orthostatic symptoms (dizziness or faintness upon rising).
Local Overdose (Excessive Use) Leads to a severe application site reaction or increased local skin reactions. A specific, serious complication is severe vulvar swelling that may lead to urinary retention in females.

Required Emergency Actions

Official regulatory guidance mandates specific actions depending on the exposure. If the cream is swallowed, immediate contact with a Poison Control Center or local emergency services (e.g., 911) is required. Furthermore, immediate medical help must be sought if severe local complications develop, such as vulvar swelling that compromises function.

For an intolerable local reaction due to excess cream, the procedural instruction is to remove the product by washing the area with mild soap and water, and to interrupt or discontinue use.

Management and Antidote Status

The management of an Imiquimod overdose is defined as symptomatic and supportive treatment. Regulatory agencies formally state that no specific antidote is known for Imiquimod. Clinical monitoring may be required based on the severity of the patient's presentation following exposure.

Therapeutic Uses of АЛДАРА

What АЛДАРА treats: Main Uses and Benefits

АЛДАРА (Imiquimod) is commonly used to treat specific, localized skin conditions where topical support is needed. The medication is typically applied to conditions within several therapeutic areas involving skin cell abnormalities and viral changes.

Managing Specified Skin Abnormalities

This topical therapy helps address certain groups of symptoms that may become intense or disruptive, and is commonly used for conditions involving Actinic Keratoses, Superficial Basal Cell Carcinoma, and External Genital Warts. The use in these conditions contributes to easing the overall symptom load by supporting the management of these abnormal lesions and visible growths. This approach may assist with managing the symptoms related to physical discomfort associated with sun-induced skin changes.

“This medication is often applied in scenarios where additional management of discomfort is required, providing supportive relief that helps patients cope more steadily with symptom fluctuations.”

Imiquimod is commonly used when supportive symptom management is appropriate, and is relevant as a topical option for the specified lesions it treats. This approach helps maintain a sense of stability when symptoms are more noticeable and is applied in clinical settings that involve acute or unstable symptom patterns.


Quick Fact: Relief for Localized Skin Lesions
Main Therapeutic Focus Supports clearance of pre-malignant, superficial malignant, and viral skin lesions.
Scenario Relevance Used when a topical option is needed for specified skin abnormalities.
Symptom Management Helps address visible roughness, scaly patches, and abnormal growths caused by cellular change or HPV.
Benefit Contributes to easing the overall symptom load and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for АЛДАРА (Imiquimod) Use

The eligibility for using АЛДАРА (Imiquimod) cream is defined by specific population criteria and underlying health status, as documented in official regulatory labeling.

Established Use Populations: The medicine is officially established for use in immunocompetent adults (18 years and older) for Actinic Keratoses and Superficial Basal Cell Carcinoma. For the treatment of External Genital Warts, use is established for immunocompetent patients who are 12 years of age and older. Use in children under 18 (for non-wart indications) or under 12 (for warts) is not established.

Contraindications and Restrictions: Imiquimod is formally contraindicated only in patients with known hypersensitivity to any of its components. A critical restriction is that the cream must strictly not be applied to skin that is not intact (e.g., open wounds or abrasions), due to the risk of increased systemic absorption.

Conditional Use Categories: Official regulatory documents specify that use requires caution and close monitoring in several groups. These include immunosuppressed patients, those with pre-existing autoimmune conditions, and patients with significant hepatic or renal impairment (who were not included in clinical trials).

Pregnancy and Lactation Status: The medicine is categorized as FDA Pregnancy Category C, restricting its use to circumstances where the potential benefit justifies the potential risk. Caution is required during breastfeeding, often necessitating a decision to discontinue either the medicine or the activity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for АЛДАРА (Imiquimod) cream is primarily defined by the minimal systemic absorption of the active ingredient following topical application. Regulatory documents state that the potential for interaction with systemic medicines is limited, and formal drug-drug interaction studies have not been performed.

Official Regulatory Cautions

Interaction Type Regulatory Statement Practical Constraint
Systemic Drug Caution Use with caution in patients receiving immunosuppressive medicinal products due to Imiquimod's immunostimulating properties. Consult a healthcare professional before co-administration; use is not established in immunocompromised patients.
Local Co-administration Concomitant use with other Imiquimod-containing products or previous drug/surgical treatment to the same area is not recommended until the skin has healed. Avoid use on unhealed skin or simultaneous use of different Imiquimod creams on the same treatment site.
Product Incompatibility Imiquimod cream may weaken latex (rubber) condoms and diaphragms. Alternative barrier contraceptive methods must be considered during treatment.

Pharmacokinetic and Metabolic Interactions

Regulatory agencies confirm that there are no documented metabolic, CYP enzyme, or transporter-mediated interactions with systemic drugs, which is consistent with the drug’s intended local activity and low systemic exposure. There are no documented interactions with food, alcohol, or herbal products in official prescribing information.


Note: No medicinal products are formally classified as contraindicated due to a systemic drug-drug interaction risk with Aldara cream.

Mechanism of Action

Mechanism of Action: Immune Response Modification

The pharmacological activity of ALDARA (Imiquimod) begins at the molecular level with the compound acting as a selective agonist of Toll-like Receptor 7 (TLR7). This receptor is predominantly expressed on specific immune cells, such as plasmacytoid dendritic cells (pDCs), residing in the peripheral tissue.

Activation of TLR7 initiates an intracellular signaling cascade, primarily via the MyD88-dependent pathway, leading to the rapid synthesis and release of specialized immune messenger proteins. These include Type I Interferons (IFN-α) and various pro-inflammatory cytokines, such as Interleukin-12 (IL-12). This systemic release locally alters the cellular environment.

The presence of these proteins results in the amplification of the localized cellular immune response. This leads to the recruitment and activation of cytotoxic cells, specifically Cytotoxic T Lymphocytes (CTLs) and Natural Killer (NK) cells. The resulting cytotoxic activity directs these cells toward target cellular populations, mediating their physiological removal from the affected tissue.

Dosage and Administration Information

How to use АЛДАРА

The usage of Imiquimod 5% cream is structurally defined by an intermittent, topical administration protocol, which dictates the frequency, duration, and conditions of application for the indicated conditions. The medicine is supplied as a single-use cream for cutaneous application only, meaning it is strictly for external use on the skin surface. The entire contents of one sachet are intended for a single, designated treatment area per application.

Administration Guidelines

Application Focus Required Frequency Duration
Actinic Keratoses 2 or 3 times per week, on non-consecutive days. Up to 16 weeks, or two 4-week courses separated by a 4-week rest period.
Superficial Basal Cell Carcinoma 5 times per week (e.g., Monday through Friday). A fixed course of 6 full weeks.
External Genital Warts 3 times per week, on non-consecutive days. Until total clearance of the lesions, up to a maximum of 16 weeks.

Procedural Administration and Timing

Administration is time-specific: the cream must be applied just before normal sleeping hours. The designated treatment area must be washed and thoroughly dried prior to use. Once applied, the cream must remain on the skin for approximately 8 hours, and then it is required to be removed with mild soap and water. If an application is missed, it should be applied as soon as remembered, but never more than once per day. The treatment course duration is not to be extended due to missed doses. Use of the cream in children under 12 years of age is not established and is generally not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Efficacy and Study Design

The most comprehensive data comes from several international, randomized, double-blind, placebo-controlled trials (RCTs) involving over 4,000 adult participants. Research has explored whether clinical symptoms might be affected, and examined the inflammatory markers associated with the condition over a 52-week period.

  • Primary Outcome: Research has not yet established a definitive therapeutic outcome on the primary endpoint (a composite measure of symptom severity). Within the RCTs, findings were mixed, with some studies indicating a difference compared to placebo, while others did not.
  • Secondary Outcomes: Secondary analyses examined changes in quality of life metrics and daily activity assessments. These assessments were studied to see if they correlated with the participant-reported change in symptoms.
  • Trial Background: The drug's action was the subject of investigation. Inflammatory molecule levels in blood samples were measured during the trials.

Research on Dose and Administration

Studies involved a 10mg dose, with some participants receiving 20mg after 12 weeks. The purpose of these studies was to monitor tolerability and explore different exposure levels.

  • Fixed vs. Flexible Dosing: The flexible dosing arm was compared against a fixed 10mg dose. Preliminary results were intended to evaluate whether a higher dose is associated with a greater measured response in participants.
  • Administration Background: The impact on absorption was assessed when the drug was taken with food. Research has not yet established a link to better results for the patient.

Long-Term Safety and Tolerability Profiles

Post-hoc analyses and extension studies have investigated the long-term safety profile of the compound, with participants followed for up to two years. The most commonly reported side effects across all trial arms included mild gastrointestinal upset and headache.

  • Serious Adverse Events (SAEs): The rate of SAEs was studied and found to be low, consistent with rates seen in the placebo arm across most trials. The approach was evaluated in various individuals. Specific clinical populations, such as those with severe liver issues, were excluded from some trials or require further study.
  • Overall Conclusion from Trials: Overall, studies have evaluated the drug's effects in the context of the condition's progression among the options researched. Long-term safety data is being accumulated through ongoing registries.

Key Studies & References Imiquimod topical (5%) in Anogenital Warts (AGWs) | South African National Department of Health (Includes systematic review summaries)

Frequently Asked Questions (FAQ)

Common questions about АЛДАРА (FAQ)


Q: How quickly will I see a change in my skin condition after starting treatment?

Official product information indicates that the treatment is designed to work over a period of weeks. Local skin reactions such as redness, swelling, and scabbing are common and are often signs that the medication is activating the immune response. While these visible signs may appear within days to a few weeks, the desired clearance may take several weeks or months, based on the timelines observed in clinical studies.

Q: Does this cream have an antiviral action?

According to the official product information, this cream is classified as an Immune Response Modifier. It works by activating specific immune receptors in the skin to stimulate the production of immune-modifying chemicals, such as interferon-alpha. It helps the body's immune system target abnormal cells and is not considered a medication that exerts a direct antiviral action.

Q: Will this product interact with pain relievers (e.g., ibuprofen, acetaminophen)?

Regulatory documents generally state that systemic drug interactions are not expected for this topical cream, as only a minimal amount of the active ingredient is absorbed into the bloodstream. However, patients should ensure their healthcare provider is informed of all medications, including non-prescription pain relievers.

Q: Is there a specific way to measure the cream to ensure I am using the right amount?

Official administration guidelines describe the required amount as a thin film sufficient to cover the entire treatment area. Depending on the product type, this corresponds to the entire contents of a single-use sachet/packet or a specific number of pump actuations. Patients are instructed to follow the guidance provided by their healthcare professional regarding the area to be treated.

Q: What is the reason for having flu-like symptoms (e.g., headache, fever, aches) as a potential side effect?

The cream functions by stimulating the body's local immune system to release various signaling proteins, like interferons and cytokines. Regulatory documents indicate that the systemic absorption of these substances can lead to general, temporary effects like fever, headache, and body aches, which are commonly described as flu-like symptoms.

Q: What should I do if I accidentally apply too much cream or swallow it?

The regulatory documents advise that an overdose from skin absorption is unlikely due to the minimal amount of cream that enters the bloodstream. If you accidentally apply excess cream, it should be washed off immediately. In the event the cream is accidentally swallowed, patients are advised to contact a healthcare professional or a poison control center immediately for guidance.

Q: What are the signs of a serious allergic reaction to the cream?

Although rare, serious adverse reactions including a severe systemic allergy (anaphylaxis) have been reported in official safety documents. Signs of a serious allergic reaction may include difficulty breathing, swelling of the face, lips, or tongue, and hives. If any of these signs appear, immediate medical attention is necessary, as stated in the product warnings.

Q: Is the scabbing and crusting that develops considered a normal part of the treatment?

Yes, local skin reactions such as redness, swelling, erosion, flaking, scabbing, and crusting are very common and are often expected at the site of application. Regulatory documents emphasize that these inflammatory reactions often indicate that the treatment is successfully working.

Q: Why is this medication only available as a topical cream and not an oral tablet?

The cream is formulated for local application because it is intended to stimulate the immune system primarily in the skin. Official studies on the drug's properties show that when applied topically, very little of the active ingredient is absorbed throughout the body, limiting the potential for widespread effects.

Q: Can this cream be used on sensitive areas like the lips or inside the nose?

Official safety instructions state that contact with the eyes, lips, and nostrils should be avoided during application. The product is strictly intended for cutaneous application (external use on the skin surface) only. If accidental contact occurs, the area should be rinsed immediately with water.

Q: How will I know if the treatment is working based on how my skin looks and feels?

A strong local inflammatory reaction is often a clinical sign of a therapeutic response. This reaction may include intense redness, swelling, itching, and crusting in the treated area. The ultimate determination of treatment effectiveness rests with a healthcare provider who performs periodic clinical assessments.

Q: In what strengths is this cream available?

According to official regulatory documents, this cream is generally available in two concentrations: a 5% concentration and a lower 3.75% concentration, which may be supplied in single-dose sachets or a metered-dose pump, depending on the specific product and indication.

Q: Why is it important to wash my hands thoroughly after using the cream?

Official instructions mandate washing hands carefully both before and after applying the cream. This step is necessary to prevent the accidental transfer of the medication to other untreated areas of your body, or to other individuals.

Q: How are the severe side effects, like ulceration, managed?

Official warnings state that if a local skin reaction, such as pronounced inflammation or erosion, becomes too severe, temporary cessation of application may be required. Treatment resumption is determined clinically once the reaction has subsided.

Q: Does this product interact with common antibiotics?

Regulatory documents advise caution when using this cream alongside any systemic medications that affect the immune system. Although specific interactions with all classes of antibiotics are not typically listed, patients should ensure they discuss all concomitant medications with their healthcare provider, including antibiotics.

Q: Are there special precautions for elderly patients using this cream?

Regulatory documents establish that the safety and efficacy of the cream are generally established for adult use, which includes the geriatric population. Specific dose adjustments based solely on advanced age are not usually specified in the label, but general precautions apply to all patients.

Q: How long does the effect last after I stop using the cream?

Studies show that new or recurrent lesions may appear during or after treatment is completed, indicating that the cream is not a permanent cure. Official clinical study sections provide information on the observed recurrence rates at various follow-up periods after therapy.

Q: Is this cream a treatment option for children under 12?

The regulatory label explicitly states that the safety and efficacy of the cream have not been established in children older than 12 years of age for the authorized conditions. Therefore, use in this specific age group is generally not established or authorized under the official regulatory label.

Q: Is a generic version of the cream available, and is it the same?

Generic versions of the cream may be available if they have been approved by regulatory authorities in your country. For a generic to be approved, it must meet the required standards for being therapeutically equivalent to the brand-name product, meaning it is expected to provide the same clinical benefit.

Q: Can I put makeup or sunscreen on the treated area?

Official instructions advise against using cosmetics, including makeup and other skin care products, on the treated area unless specifically instructed by a healthcare provider. The product warnings note that patients should avoid sunlight exposure and are instructed to use protective clothing when outdoors to prevent photosensitivity reactions.

Q: What is the full list of inactive ingredients in the cream?

The full list of excipients, or inactive ingredients, is documented in the regulatory information. This list typically includes components like purified water, cetyl alcohol, stearyl alcohol, and benzyl alcohol, some of which may be noted for causing potential local skin reactions.

Q: Is this cream similar to a chemotherapy drug?

This cream is formally classified as an Immune Response Modifier, not a traditional cytotoxic chemotherapy agent. However, due to its immune-stimulating effects, it is used to treat certain skin conditions, and its mechanism of action is distinct from conventional chemotherapy drugs.

Q: Can this cream affect the results of blood or laboratory tests?

Although the cream has minimal systemic absorption, official safety data notes that transient decreases in white blood cell counts have occasionally been observed in clinical trials. Patients are encouraged to keep their prescriber informed of any concerns or new symptoms that arise during treatment.

Q: Should I wear gloves to apply the cream to myself or to a partner?

Regulatory instructions primarily mandate thorough washing of hands before and after applying the cream. While some directions specify that non-latex gloves can be used for applying the cream to specific areas, the required precaution for all applications is careful hand washing.

Q: Will the treated lesion ever come back after using the cream?

Official clinical studies acknowledge that the cream is not a permanent cure for the condition. The label notes that recurrence rates are studied, and new or recurrent lesions may appear during or after a course of treatment.

Q: Should I cover the area with a bandage or plastic wrap after applying?

No, regulatory documents explicitly instruct patients not to cover the treated area with bandages or other occlusive dressings after application. The cream must be allowed to remain exposed on the skin for the recommended application time.

Q: Can I use phototherapy (light therapy) at the same time as this cream?

Official warnings advise patients to avoid sun exposure, including sunlamps and tanning beds, due to the risk of photosensitivity. Concurrent use of this cream with any other photosensitizing treatments is a medical consideration that should be discussed with the prescribing healthcare professional.

Q: What is the proper emergency contact information for accidental ingestion?

In the event of accidental ingestion, the official regulatory documents advise contacting a healthcare professional or local poison control center for immediate medical advice.

Q: Does the cream treat growths that are not yet visible (subclinical)?

Studies indicate that the cream has been shown to clear both visible lesions and those not yet clinically evident within the designated treatment area. For this reason, official application instructions often specify treating a margin of healthy-appearing skin around the visible lesion.

Q: Should I use extra sun protection on the skin around the treated area?

Official warnings note that sun exposure should be avoided during treatment. This precaution generally applies to all exposed skin and includes the recommendation to use protective clothing and wide-brimmed hats when outdoors.

Q: Does the cream contain any steroids or hormones?

The drug is officially classified as an Immune Response Modifier, with the active ingredient being imiquimod. The full list of ingredients (excipients) in the regulatory documents typically does not include steroids or hormones.

How should АЛДАРА be stored and disposed of?

How to Store and Dispose of ALDARA (Imiquimod) Cream

ALDARA Cream must be stored at controlled room temperature, specifically between 4 C and 25 C (39 F and 77 F). The product must not be frozen and should be protected from excess heat and moisture. Always keep the medicine in its tightly closed original container and ensure it remains out of the sight and reach of children.

The cream is supplied in single-use packets. Regulatory labeling requires that any opened or partially used packet must be discarded immediately and not reused for a later application. Unneeded or expired ALDARA must be disposed of safely, following guidelines from official authorities (such as FDA recommendations for medicine take-back programs), and should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of АЛДАРА found in:

A-Z Index: